Ipsen Biopharmaceuticals Canada Inc., a partner of Exelixis, Inc., received approval from Health Canada of Cabometyx (cabozantinib) tablets for the treatment of adults with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF) targeted therapy. Health Canada granted Cabometyx priority review status, which provided an accelerated review of Ipsen’s new drug submission.…